›› 2012, Vol. 32 ›› Issue (3): 361-.doi: 10.3969/j.issn.1674-8115.2012.03.027

• Review • Previous Articles     Next Articles

Advances in treatment of IgA nephropathy

JIA Xiao-yuan, WANG Wei-ming   

  1. Department of Nephrology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
  • Online:2012-03-28 Published:2012-03-28


IgA nephropathy (IgAN) is the most common glomerulus disease in the world, and IgAN accounts for 45.2% to 58.2% of primary glomerulonephritis in China. The pathogenesis of IgAN remains unknown, and angiotensin converting enzyme inhibitor (ACEI)/angiotensin Ⅱ receptor blocker (ARB), corticosteroid and immunosuppressive agents are widely used in clinics. However, there has been no unified standard in IgAN therapy.In 2010 Renal Week of American Society of Nephrology (ASN), Kidney Disease Improving Global Outcomes (KDIGO) put forward suggestions on the treatment of IgAN based on evidence-based medicine. In this paper, these suggestions are reviewed.

Key words: IgA nephropathy, treatment, ACEI/ARB, corticosteroid, immunosuppressive agent, fish oil, antiplatelet agent, tonsillectomy